Colin Pritchard
Molecular Genetic Pathology · Seattle, WANPI 1457550022
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,655 of the $6,655 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Astrazeneca UK Limited.
Across 1 payment — averaging $6655.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$7K
Across 6 payments — averaging $107,686 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Foundation Medicine, Inc.$602K
- Novo Nordisk US Research & Development, Inc.$44K
What the payments were for
- Consulting fees$6,655100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 1 | $6,655 |
How this compares
Too few molecular genetic pathology providers in Washingtonto place this figure against a meaningful peer group, so we don't.
Other molecular genetic pathology in Seattle
- Eric KonnickSeattle$27K
- Sean KeenanSeattle$15
- Charles SaileyVancouver$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.